DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety of Remifentanil Infusion

Information source: Diskapi Teaching and Research Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Urinary Tract Problem

Intervention: remifentanil (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Diskapi Teaching and Research Hospital

Official(s) and/or principal investigator(s):
Jülide Ergil, MD, Study Chair, Affiliation: Ministry of Health Dıskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1.
Alp Alptekin, MD, Study Chair, Affiliation: Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1
Nihan Aktürk, MD, Study Chair, Affiliation: Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital , Anesthesiology 1
Haluk Gümüs, MD, Study Chair, Affiliation: Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1

Summary

The effect of maintenance remifentanil infusion with target controlled infusion during laryngeal mask airway removal on hemodynamic parameters and emergence quality is going to be investigated.

Clinical Details

Official title: The Effects of Maintenance a Remifentanil Infusion on the Hemodynamic Variables and Recovery Quality

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Smooth cLMA Removal Condition (Score 1)

Detailed description: In all patients (control group and remifentanil group induction of anesthesia will be achieved with desflurane and remifentanil. Anesthesia will be maintained with remifentanil (1-4 ng/mL) by TCI target controlled infusion, and desflurane . Throughout the surgery hemodynamic parameters are going to be recorded. As soon as the surgery has been finished, in control group remifentanil infusion and desflurane inhalation is going to be stopped. In remifentanil group,desflurane inhalation is going to be stopped and remifentanil infusion will be maintained until the removal of LMA. During the emergence period the time of eye opening, hemodynamic parameters and emergence quality (score 1-2)are going to be recorded.

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- ASA I-II status

- aged 18-60 years old

- presenting for ureterorenoscopy

Exclusion Criteria:

- history of hypertension

- asthma and chronic obstructive lung disease

- recent respiratory tract infections

Locations and Contacts

Ministry of Health Diskapi Yildirim Beyazit Research and Training Hospital departement of 1. Anesthesiology, Ankara 06110, Turkey
Additional Information

Starting date: February 2011
Last updated: June 15, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017